BC Extra | Dec 12, 2019
Financial News

Trio of follow-ons lift 2019 tally of deals

December’s rush of follow-ons has continued with Rocket, Constellation and Marinus all pricing follow-on offerings since Tuesday’s close to raise more than $340 million. But cash raised via follow-ons continues to lag behind last year's...
BC Extra | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
BioCentury | Mar 30, 2019
Product Development

Sage broadens the spotlight on postpartum depression

Sage is parlaying the launch of the first drug for postpartum depression into improved awareness and diagnosis, setting up its next therapy to launch into a larger, better prepared market. On March 19, FDA approved...
BC Extra | Feb 26, 2019
Company News

Management tracks: Immunomedics, Daiichi, Notable Labs

Immunomedics Inc. (NASDAQ:IMMU) said Michael Pehl resigned as president, CEO and a board member due to personal reasons, just 15 months after he joined the antibody-drug conjugate company. The news comes a month after FDA...
BC Extra | Dec 7, 2017
Clinical News

Sage jumps on Phase II data for MDD candidate

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $64.37 (70%) to $156.27 on Thursday after reporting that SAGE-217 met the primary endpoint in a Phase II trial to treat moderate to severe major depressive disorder. Sage added over...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Sep 22, 2017
Financial News

Follow-on roundup: Array, Marinus, T2

Cancer company Array BioPharma Inc. (NASDAQ:ARRY), neurology company Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), and diagnostics play T2 Biosystems Inc. (NASDAQ:TTOO) each priced follow-on offerings, raising more than $270 million. Array raised $258.8 million through the sale...
BC Extra | Sep 15, 2017
Financial News

Follow-on roundup: Array, Marinus, T2

Cancer company Array BioPharma Inc. (NASDAQ:ARRY), neurology company Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), and diagnostics play T2 Biosystems Inc. (NASDAQ:TTOO) each priced follow-on offerings, raising more than $270 million. Array raised $225 million late Thursday through...
BC Week In Review | Jan 27, 2017
Clinical News

Ganaxolone: Preliminary Ph II data

Preliminary data from 4 patients with cyclin dependent kinase like 5 (CDKL5) epilepsy in an open-label, U.S. and Italian Phase II trial showed that once-daily doses of up to 1,800 mg/kg oral ganaxolone for an...
Items per page:
1 - 10 of 54
BC Extra | Dec 12, 2019
Financial News

Trio of follow-ons lift 2019 tally of deals

December’s rush of follow-ons has continued with Rocket, Constellation and Marinus all pricing follow-on offerings since Tuesday’s close to raise more than $340 million. But cash raised via follow-ons continues to lag behind last year's...
BC Extra | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
BioCentury | Mar 30, 2019
Product Development

Sage broadens the spotlight on postpartum depression

Sage is parlaying the launch of the first drug for postpartum depression into improved awareness and diagnosis, setting up its next therapy to launch into a larger, better prepared market. On March 19, FDA approved...
BC Extra | Feb 26, 2019
Company News

Management tracks: Immunomedics, Daiichi, Notable Labs

Immunomedics Inc. (NASDAQ:IMMU) said Michael Pehl resigned as president, CEO and a board member due to personal reasons, just 15 months after he joined the antibody-drug conjugate company. The news comes a month after FDA...
BC Extra | Dec 7, 2017
Clinical News

Sage jumps on Phase II data for MDD candidate

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $64.37 (70%) to $156.27 on Thursday after reporting that SAGE-217 met the primary endpoint in a Phase II trial to treat moderate to severe major depressive disorder. Sage added over...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Sep 22, 2017
Financial News

Follow-on roundup: Array, Marinus, T2

Cancer company Array BioPharma Inc. (NASDAQ:ARRY), neurology company Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), and diagnostics play T2 Biosystems Inc. (NASDAQ:TTOO) each priced follow-on offerings, raising more than $270 million. Array raised $258.8 million through the sale...
BC Extra | Sep 15, 2017
Financial News

Follow-on roundup: Array, Marinus, T2

Cancer company Array BioPharma Inc. (NASDAQ:ARRY), neurology company Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), and diagnostics play T2 Biosystems Inc. (NASDAQ:TTOO) each priced follow-on offerings, raising more than $270 million. Array raised $225 million late Thursday through...
BC Week In Review | Jan 27, 2017
Clinical News

Ganaxolone: Preliminary Ph II data

Preliminary data from 4 patients with cyclin dependent kinase like 5 (CDKL5) epilepsy in an open-label, U.S. and Italian Phase II trial showed that once-daily doses of up to 1,800 mg/kg oral ganaxolone for an...
Items per page:
1 - 10 of 54